Current understanding of cardiotoxicity diagnostics in patients with multiple myeloma during autologous hematopoietic stem cell transplantation
https://doi.org/10.17021/1992-6499-2025-2-08-26
Abstract
This review presents current laboratory and instrumental methods for cardiovascular toxicity diagnosing in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. In the absence of national guidelines on the timing and frequency of monitoring, it is particularly important to have a set of techniques to detect preclinical stages of myocardial dysfunction. The most useful methods include transthoracic echocardiography, with assessment of global longitudinal strain using speckle tracking, and measurement of cardiac biomarkers such as troponin T and I, and natriuretic peptides. Using this combination of methods allows for early detection of cardiotoxicity, which is essential for timely intervention and treatment.
Keywords
cardiotoxicity,
multiple myeloma,
autologous hematopoietic stem cell transplantation,
troponins,
natriuretic peptides,
echocardiography,
global longitudinal strain
Supporting agencies: The authors declare that there is no external funding for the exploration and analysis work
About the Authors
V. S. Podsevalov
Samara State Medical University
Russian Federation
Russian Federation
Vladimir S. Podsevalov - Assistant of the Department.
Samara
V. D. Sabanova
Samara State Medical University
Russian Federation
Russian Federation
Victoria D. Sabanova - Assistant of the Department.
Samara
O. A. Germanova
Samara State Medical University
Russian Federation
Russian Federation
Olga A. Germanova - Dr. Sci. (Med.), Director of the International Research Center.
Samara
I. L. Davydkin
Samara State Medical University
Russian Federation
Russian Federation
Igor L. Davydkin - Dr. Sci. (Med.), Professor, Head of the Department, Director of the Research Institute.
Samara
References
1. Jain D., Russell R. R., Schwartz R. G., Panjrath G. S., Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Current Cardiology Reports. 2017; 19, (5); 36. doi: 10.1007/s11886-017-0846-x.
2. Schlitt A., Jordan K., Vordermark D., Schwamborn J., Langer T., Thomssen C. Cardiotoxicity and oncological treatments. Deutsches Ärzteblatt International. 2014; 111 (10): 161–168. doi: 10.3238/arztebl.2014.0161.
3. Silver R. T., Woolf S. H., Hehlmann R., Appelbaum F. R., Anderson J., Bennett C., Goldman J. M., Guilhot F., Kantarjian H. M., Lichtin A. E., Talpaz M., Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999; 94 (5): 1517–1536.
4. Cortes J. E., Saglio G., Kantarjian H. M., Baccarani M., Mayer J., Boqué C., Shah N. P., Chuah C., Casanova L., Bradley-Garelik B., Manos G., Hochhaus A. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. Journal of Clinical Oncology. 2016; 34 (20): 2333–2340. doi: 10.1200/JCO.2015.64.8899.
5. Hochhaus A., Saglio G., Hughes T. P., Larson R. A., Kim D. W., Issaragrisil S., le Coutre P. D., Etienne G., Dorlhiac-Llacer P. E., Clark R. E., Flinn I. W., Nakamae H., Donohue B., Deng W., Dalal D., Menssen H. D., Kantarjian H. M. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30 (5): 1044–1054. doi: 10.1038/leu.2016.5.
6. Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., Lange E., Köppler H., Kiehl M., Sökler M., Schlag R., Vehling-Kaiser U., Köchling G., Plöger C., Gregor M., Plesner T., Trneny M., Fischer K., Döhner H., Kneba M., Wendtner C. M., Klapper W., Kreuzer K. A., Stilgenbauer S., Böttcher S., Hallek M.; International group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 2016; 17 (7): 928–942. doi: 10.1016/S1470-2045(16)30051-1.
7. Mateos M. V., Sonneveld P., Hungria V., Nooka A. K., Estell J. A., Barreto W. G., Corradini P., Min C., Medvedova E., Weisel K. C., Chiu C., Schecter J., Amin H., Qin X., Qi M., Spencer A. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients with multiple myeloma (MM): four-year update of CASTOR. Journal of Clinical Oncology. 2019; 37 (15); suppl.: 8040.
8. Kravchenko J., Berry M., Arbeev K. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer. 2015; 88 (1): 85–93.
9. Thomas E. D., Lochte H. L., Lu W. C., Ferrebee J. W. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New England Journal of Medicine. 1957; 257 (1): 491–496. doi: 10.1056/nejm195709122571102.
10. Appelbaum F. R., Sullivan K. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Hill R., Mortimer J., Neiman P. E., Sanders J. E., Singer J. E., Stewart P., Storb R. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology. 1987: 5 (9): 1340–1347.
11. Phillips G. L., Reece D. E. Clinical studies of autologous bone marrow transplantation in Hodgkin’s disease. Clinical Haematology. 1986; 15 (1): 151–166.
12. Phelan R., Chen M., Bupp C., Bolon Y. T., Broglie L., Brunner-Grady J., Burns L. J., Chhabra S., Christianson D., Cusatis R., Devine S. M., D'Souza A., Eapen M., Hamadani M., Hengen M., Lee S. J., Moskop A., Page K. M., Pasquini M., Pérez W. S., Riches M., Rizzo D., Saber W., Spellman S. R., Stefanski H. E., Steinert P., Weisdorf D., Horowitz M., Auletta J. J., Shaw B. E., Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Therapy. 2022; 28 (7): 409.e1–409.e10. doi: 10.1016/j.jtct.2022.04.012.
13. Maschan M. A., Skorobogatova E. V., Shelikhova L. N., Balashov D. N., Blagonravova O. L., Dolgopolov I. S., Subbotina N. N., Vakhonina L. V., Fechina L.G., Mentkevich G.L., Paina O. V., Gevorgian A. G., Bykova T. A., Dinikina Iu. V., Subora A. Iu., Bronin G. O., Alianskii A. L., Novichkova G. A., Maschan A. A., Zubarovskaia L. S. Hematopoietic stem cell transplantation in children in Russia: a brief overview of activity in 2015– 2018. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2020; 19 (2): 22–29. (In Russ.).
14. Kostroma I. I., Zherniakova A. A., Zapreeva I. M., Sidorova Zh. Iu., Semenova N. Iu., Kariagina E. V., Stepchenkova E. I., Bessmeltcev S. S., Chechetkin A. V., Gritcaev S. V. A retrospective analysis of the survival of patients with multiple myeloma after autologous hematopoietic stem cell transplantation. Klinicheskaia onkogematologiia = Clinical oncohematology. 2021; 14 (1): 73–79. (In Russ.).
15. Olson T. L., Pollack M. M., Dávila Saldaña B. J., Patel A. K. Hospital survival following pediatric HSCT: changes in complications, ICU therapies and outcomes over 10 years. Frontiers in Pediatrics. 2023; 11; 1247792. doi: 10.3389/fped.2023.1247792.
16. Bhatia S., Dai C., Landier W., Hageman L., Wu J., Schlichting E., Siler A., Funk E., Hicks J., Lim S., Balas N., Bosworth A., Te H. S., Francisco L., Bhatia R., Salzman D., Goldman F. D., Forman S. J., Weisdorf D. J., Wong F. L., Armenian S. H., Arora M. Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS report. Journal of Clinical Oncology. 2022; 40: 1991–2003. doi: 10.1200/JCO.21.02372.
17. Baker J. K., Shank-Coviello J., Zhou B., Dixon J., McCorkle R., Sarpong D., Medoff E., Cooper D., Seropian S., Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma, Myeloma & Leukemia. 2020; 20 (4): 244–251.e4. doi: 10.1016/j.clml.2019.12.027.
18. Gent D. G., Saif M., Dobson R., Wright D. J. Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults: JACC: CardioOncology State of the Art Review. JACC: CardioOncology. 2024; 6 (4): 475–495. DOI: 10.1016/j.jaccao.2024.06.004.
19. Krishan S., Asad Z. U. A., Quiroga D., Ghazi S. M., Quartermaine C., Braunstein Z., Kola-Kehinde O., Shaaban A., Habib A., Khan S., Cheng R., Brammer J. E., Addison D. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample. Scientific Reports. 2024; 14; 16829. doi: 10.1038/s41598024-65294-9.
20. Vasbinder A., Hoeger C. W., Catalan T., Anderson E., Chu C., Kotzin M., Xie J., Kaakati R., Berlin H. P., Shadid H., Perry D., Pan M., Takiar R., Padalia K., Mills J., Meloche C., Bardwell A., Rochlen M., Blakely P., Leja M., Banerjee M., Riwes M., Magenau J., Anand S., Ghosh M., Pawarode A., Yanik G., Nathan S., Maciejewski J., Okwuosa T., Hayek S. S. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors. JACC: CardioOncology. 2023; 5 (6): 821–832. doi: 10.1016/j.jaccao.2023.07.007.
21. Mandala E., Lafara K., Kokkinovasilis D., Kalafatis I., Koukoulitsa V., Katodritou E., Lafaras C. Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review. Life. 2024; 14; 524. doi: 10.3390/life14040524.
22. Alizadehasl A., Ghadimi N., Hosseinifard H., Roudini K., Emami A. H., Ghavamzadeh A., KhodaAmorzideh D. Cardiovascular diseases in patients after hematopoietic stem cell transplantation: systematic review and meta-analysis. Current Research in Translational Medicine. 2023; 71 (1); 103363. doi: 10.1016/j.retram.2022.103363.
23. Hayek S. S., Zaha V. G., Bogle C., Deswal A., Langston A., Rotz S., Vasbinder A., Yang E., Okwuosa T., American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine, the Council on Cardiovascular and Stroke Nursing. Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: from pretransplantation to survivorship: a scientific statement from the American Heart Association. Circulation. 2024; 149 (16): e1113–e1127. doi: 10.1161/CIR.0000000000001220.
24. Yin X., Fan F., Zhang B., Hu Y., Sun C. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Therapeutic Advances in Hematology. 2022; 13; 20406207221086755. doi: 10.1177/20406207221086755.
25. Lyon A. R., López-Fernández T., Couch L. S., Asteggiano R., Aznar M. C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D. J., de Azambuja E., de Boer R. A., Dent S. F., Farmakis D., Gevaert S. A., Gorog D. A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S. S., Stephens R., Suter T. M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C. G., van der Meer P., van der Pal H. J. H., ESC Scientific Document Group 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International CardioOncology Society (IC-OS). European Heart Journal. 2022; 43 (41): 4229–4361. doi: 10.1093/eurheartj/ehac244.
26. Savchenko V. G., Mendeleeva L. P., Parovichnikova E. N. i dr. Autologous hematopoietic stem cell transplantation in hemoblastosis: a methodological guide. Moscow: 2020: 96 p. (In Russ.).
27. Multiple myeloma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Moscow: 2025: 89 p. (In Russ.).
28. Danilova O. E., Gimatdinova G. R., Davydkin I. L., Tereshina O. V., Sabanova V. D., Davydkin G. I. New approaches to the assessment of cardiovascular toxicity in patients with hematological malignant tumors (review). Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaia praktika = Clinical oncohematology. Fundamental research and clinical practice. 2023; 16 (3): 331–336 (In Russ.).
29. Sabanova V. D., Naumova K. V., Cherenova S. G., Davydkin I. L. Endothelial dysfunction in patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors. Clinical Oncohematology. Fundamental Research and Clinical Practice. 2024; 17 (S3): 72–73.
30. Cherenova S. G., Naumova K. V., Davydkin I. L., Stepanova T. Iu., Sabanova V. D. Use of Bosutinib for the Treatment of Patients with Chronic Myeloid Leukemia and Its Impact on the Cardiovascular System (review). Byulleten meditcinskoy nauki = Bulletin of medical science. 2023; 1: 141–146. doi: 10.31684/25418475-2023-1-141 (In Russ.).
31. Rotz S. J., Ryan T. D., Jodele S., Jefferies J. L., Lane A., Pate A., Hirsch R., Hlavaty J., Levesque A. E., Taylor M. D., Cash M., Myers K. C., El-Bietar J. A., Davies S. M., Dandoy C. E. The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. Bone Marrow Transplantation. 2017; 52 (8): 1171–1179. doi: 10.1038/bmt.2017.62.
32. Potemkina N. A. Cardiovascular research methods in assessing the risk of high-dose chemotherapy and hematopoietic stem cell transplantation in patients with hemoblastosis: Abstract of thesis of Candidate of Medical Sciences. Moscow: 2024: 24 p. (In Russ.).
33. Sarzhevskii V. O., Kolesnikova D. S., Melnichenko V. Ia. Biochemical markers of cardiotoxicity of highdose chemotherapy with autologous hematopoietic stem cell transplantation in malignant lymphoproliferative diseases. Klinicheskaia onkogematologiia = Clinical oncohematology. 2016; 9 (4): 465–473 (In Russ.).
34. Kolesnikova D. S. Assessment of cardiotoxic effects of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in malignant lymphomas: Abstract of thesis of Candidate of Medical Sciences. Moscow: 2017. 25 p. (In Russ.).
35. Uchida K., Yuan X., McArthur J., Lassiter R., Pan H., Keerthi D., Tsai K., Avent Y., Hines M., Martinez H. R., Qudeimat A., Ghafoor S. Elevation of NT-proBNP levels in pediatric and young adult hematopoietic stem cell transplant patients with endotheliopathy. Pediatric Reports. 2024; 16 (4): 934–944. doi: 10.3390/pediatric16040080.
36. Roziakova L., Bojtarova E., Mistrik M., Dubrava J., Gergel J., Lenkova N., Mladosievicova B. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. Journal of Experimental & Clinical Cancer Research. 2012; 31; 13. doi: 10.1186/1756-9966-31-13.
37. Se Z., Zhou H., Li H., Sun J., Zhan Q., Zeng Q., Liu Q., Xu D. Clinical characteristics of patients with different N-terminal probrain natriuretic peptide levels after hematopoietic stem cell transplantation. Disease Markers. 2020; 8839336. doi: 10.1155/2020/8839336.
38. Chaulin A. M., Grigoreva Iu. V. The main aspects of biochemistry and physiology of cardiac troponins. // Mezhdunarodnyy nauchno-issledovatelskiy zhurnal = International Research Journal. 2020; 6 (96): 129–133. doi: 10.23670/IRJ.2020.96.6.064 (In Russ.).
39. Cardinale D., Iacopo F., Cipolla C. M. Cardiotoxicity of Anthracyclines. Frontiers in Cardiovascular Medicine. 2020; 7; 26. doi: 10.3389/fcvm.2020.00026.
40. Chauin A. The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis. Vascular Health and Risk Management. 2021; 17: 601–617. doi: 10.2147/VHRM.S327661.
41. Michel L., Mincu R. I., Mahabadi A. A., Settelmeier S., Al-Rashid F., Rassaf T., Totzeck M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis. European Journal of Heart Failure. 2020; 22: 350–361. doi: 10.1002/ejhf.1631.
42. de Almeida L. B., Laterza M. C., Rondon M. U. P. B., Toschi-Dias E., de Matos L. D. N. J., Oliveira C. C., Trevizan P. F., Martinez D. G. High-dose chemotherapy impairs cardiac autonomic control of hospitalized cancer patients undergoing autologous hematopoietic stem cell transplantation. Clinical Lymphoma, Myeloma and Leukemia. 2023; 23 (3): e131–e138. doi: 10.1016/j.clml.2022.12.010.
43. Jones M., O'Gorman P., Kelly C., Mahon N., Fitzgibbon M. C. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2017; 54 (1): 149–157. doi: 10.1177/0004563216650464.
44. Levina V. D., Poltavskaia M. G., Chomakhidze P. Sh., et al. Highly sensitive troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer drugs for the treatment of breast cancer in patients with a predominantly low and intermediate risk of cardiotoxicity. Rossiiskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27 (11): 5210. doi: 10.15829/1560-4071-2022-5210 (In Russ.).
45. Lv X., Pan C., Guo H., Chang J., Gao X., Wu X., Zhi X., Ren C., Chen Q., Jiang H., Zhao X., Liu K., Li Y. Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a metaanalysis. ESC Heart Failure. 2023; 10 (4): 2170–2182. doi: 10.1002/ehf2.14373.
46. Gangaraju R., Chen Y., Hageman L., Landier W., Balas N., Ross E., Francisco L., Bosworth A., Te H. S., Wong F. L., Weisdorf D. J., Bhatia R., Forman S. J., Armenian S. H., Bhatia S. Prediction of coronary heart disease events in blood or marrow transplantation recipients. JACC: CardioOncology. 2023; 5 (4): 504–517. doi: 10.1016/j.jaccao.2023.03.013.
47. Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., Kurabayashi M., Yamaoki K., Mitani K., Hirai H., Nagai R., Yazaki Y. Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal. 1998; 136 (2): 362–363. doi: 10.1053/hj.1998.v136.89908.
48. Hall C. NT-ProBNP: the mechanism behind the marker. Journal of Cardiac Failure. 2005; 11 (5): S81–S83. doi: 10.1016/j.cardfail.2005.04.019.
49. Galiavich A. S., Tereshchenko S. N., Uskach T. M., et al. Chronic heart failure. Clinical guidelines for 2024. Rossiiskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024; 29 (11): 6162. doi: 10.15829/1560-4071-2024-6162 (In Russ.).
50. Madamanchi C., Alhosaini H., Sumida A., Runge M. S. Obesity and natriuretic peptides, BNP and NTproBNP: mechanisms and diagnostic implications for heart failure. International Journal of Cardiology. 2014; 176 (3): 611–617. doi: 10.1016/j.ijcard.2014.08.007.
51. Kumar L., Vijayvergiya R., Jain A., Singh C., Jain A., Prakash G., Khadwal A., Malhotra P. Incidence, risk factors and early prediction of doxorubicin-induced cardiotoxicity by global longitudinal strain and cardiac biomarkers in Indian patients with lymphoma: a prospective observational study. Clinical Lymphoma, Myeloma and Leukemia. 2025; 25 (3): e143–e150.
52. Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Gonerska M., Sobieszczańska M., Poręba R. Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies. Medical Oncology. 2018; 35 (12); 162. doi: 10.1007/s12032-018-1221-5.
53. Attanasio U., Di Sarro E., Tricarico L., Di Lisi D., Armentaro G., Miceli S., Fioretti F., Deidda M., Correale M., Novo G., Sciacqua A., Nodari S., Cadeddu C., Tocchetti C. G., Palazzuoli A., Mercurio V. Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond. Biomolecules. 2024; 14 (2): 199. doi: 10.3390/biom14020199.
54. Murtagh G., Januzzi J. L., Scherrer-Crosbie M., Neilan T. G., Dent S., Ho J. E., Appadurai V., McDermott R., Akhter N. Circulating cardiovascular biomarkers in cancer therapeutics-related cardiotoxicity: review of critical challenges, solutions, and future directions. Journal of the American Heart Association. 2023; 12 (21): e029574. doi: 10.1161/JAHA.123.029574.
55. Joolharzadeh P., Rodriguez M., Zaghlol R., Pedersen L. N., Jimenez J., Bergom C., Mitchell J. D. Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology. Current Cardiology Reports. 2023; 25 (3): 133–146. doi: 10.1007/s11886-022-01834-x.
56. Graf I., Greiner G., Marculescu R., Gleixner K. V., Herndlhofer S., Stefanzl G., Knoebl P., Jäger U., Hauswirth A., Schwarzinger I., Thalhammer R., Kundi M., Hoermann G., Mitterbauer-Hohendanner G., Valent P., Sperr W. R. N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. American Journal of Hematology. 2023; 98 (2): 290–299. doi: 10.1002/ajh.26805.
57. Habibollahzadeh N., Yavari S., Mirazimi Y., Aghayan A. H., Davoudian A., Rafiee M. MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review. BMC Cancer. 2024; 24; 890. doi: 10.1186/s12885-024-12640-9.
58. Moscoso I., Rodríguez-Mañero M., Cebro-Márquez M., Vilar-Sánchez M. E., Serrano-Cruz V., VidalAbeijón I., Martínez-Monzonís M. A., Mazón-Ramos P., Pedreira M., González-Juanatey J. R., Lage R. Transforming cardiotoxicity detection in cancer therapies: the promise of microRNAs as precision biomarkers. International Journal of Molecular Sciences. 2024; 25 (22); 11910. doi: 10.3390/ijms252211910.
59. Alexandraki A., Papageorgiou E., Zacharia M., Keramida K., Papakonstantinou A., Cipolla C. M., Tsekoura D., Naka K., Mazzocco K., Mauri D., Tsiknakis M., Manikis G. C., Marias K., Marcou Y., Kakouri E., Konstantinou I., Daniel M., Galazi M., Kampouroglou E., Ribnikar D., Brown C., Karanasiou G., Antoniades A., Fotiadis D., Filippatos G., Constantinidou A. New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review. Cancers. 2023; 15 (13); 3290. doi: 10.3390/cancers15133290.
60. Lakhani H. V., Pillai S. S., Zehra M., Dao B., Tirona M. T., Thompson E., Sodhi K. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Scientific Reports. 2021; 11; 7954. doi: 10.1038/s41598-021-87209-8. PMID: 33846495. PMCID: PMC8041906.
61. Dong R., Zhang M., Hu Q., Zheng S., Soh A., Zheng Y., Yuan H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). International Journal of Molecular Medicine. 2018; 41 (2): 599–614. doi: 10.3892/ijmm.2017.3311.
62. Sharma U. C., Pokharel S., van Brakel T. J., van Berlo J. H., Cleutjens J. P., Schroen B., André S., Crijns H. J., Gabius H. J., Maessen J., Pinto Y. M. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110 (19): 3121–3128. doi: 10.1161/01.CIR.0000147181.65298.4D.
63. Srivatsan V., George M., Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? European Journal of Preventive Cardiology. 2015; 22 (9): 1096–1110. doi: 10.1177/2047487314552797.
64. Chen A., Hou W., Zhang Y., Chen Y., He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. International Journal of Cardiology. 2015; 182: 168–170. doi: 10.1016/j.ijcard.2014.12.137.
65. Poręba M., Gać P., Usnarska-Zubkiewicz L., Pilecki W., Kuliczkowski K., Mazur G., Sobieszczańska M., Poręba R. The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. Annals of Noninvasive Electrocardiology. 2018; 23 (4): e12534. doi: 10.1111/anec.12534.
66. Spînu Ș., Cismaru G., Boarescu P. M., Istratoaie S., Negru A. G., Lazea C., Căinap S. S., Iacob D., Grosu A. I., Saraci G., Burz C., Cismaru A. C. ECG markers of cardiovascular toxicity in adult and pediatric cancer treatment. Disease Markers. 2021; 6653971. doi: 10.1155/2021/6653971.
67. Miller W. P., Shanley R., Dorostkar P. Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center. Bone Marrow Transplantation. 2015; 50 (7): 954–960. doi: 10.1038/bmt.2015.64.
68. Vasyuk Yu. A., Gendlin G. E., Emelina E. I., et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Rossiiskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26 (9): 4703. doi: 10.15829/1560-4071-2021-4703 (In Russ.).
69. Watanabe M., Yakushijin K., Tanaka H., Chijiki R., Saeki M., Hirakawa Y., Takakura H., Usui Y., Ichikawa H., Sakai R., Matsumoto S., Nagao S., Mizutani Y., Kurata K., Kitao A., Miyata Y., Saito Y., Kawamoto S., Yamamoto K., Ito M., Matsuoka H., Minami H. Global longitudinal strain is superior to ejection fraction for long-term follow-up after allogeneic hematopoietic stem cell transplantation. eJHaem. 2022; 4 (1): 192–198. doi: 10.1002/jha2.586.
70. Thavendiranathan P., Poulin F., Lim K. D., Plana J. C., Woo A., Marwick T. H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology. 2014; 63 (25), pt. A: 2751–2768. doi: 10.1016/j.jacc.2014.01.073.
71. Oikonomou E. K., Kokkinidis D. G., Kampaktsis P. N., Amir E. A., Marwick T. H., Gupta D., Thavendiranathan P. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiology. 2019; 4: 1007–1018. doi: 10.1001/jamacardio.2019.2952.
72. Voigt J. U., Pedrizzetti G., Lysyansky P., Marwick T. H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J. H., Hamilton J., Sengupta P. P., Kolias T. J., d'Hooge J., Aurigemma G. P., Thomas J. D., Badano L. P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European Heart Journal – Cardiovascular Imaging. 2015; 16 (1): 1–11.
73. Park J. J., Park J. B., Park J. H., Cho G. Y. Global longitudinal strain to predict mortality in patients with acute heart failure. Journal of the American College of Cardiology. 2018; 71 (18): 1947–1957.
74. Wei X., Lin L., Zhang G., Zhou X. Cardiovascular magnetic resonance imaging in the early detection of cardiotoxicity induced by cancer therapies. Diagnostics. 2022; 12 (8); 1846. doi: 10.3390/diagnostics12081846.
75. Omidi A., Weiss E., Trankle C. R., Rosu-Bubulac M., Wilson J. S. Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review. Cardio-Oncology. 2023; 9 (1); 24. doi: 10.1186/s40959-023-00175-0.
76. Vaitiekiene A., Kulboke M., Bieseviciene M., Jankauskas A., Bartnykaite A., Rinkuniene D., Strazdiene I., Lidziute E., Jankauskaite D., Gaidamavicius I., Bucius P., Lapinskas T., Gerbutavicius R., Juozaityte E., Vaskelyte J. J., Vaitiekus D., Sakalyte G. T1 mapping in cardiovascular magnetic resonance a marker of diffuse myocardial fibrosis in patients undergoing hematopoietic stem cell transplantation. Journal of Personalized Medicine. 2024; 14 (4); 412. doi: 10.3390/jpm14040412.
77. Paiman E. H. M., Louwerens M., Bresters D., Westenberg J. J. M., Tao Q., van der Geest R. J., Lankester A. C., Roest A. A. W., Lamb H. J. Late effects of pediatric hematopoietic stem cell transplantation on left ventricular function, aortic stiffness and myocardial tissue characteristics. Journal of Cardiovascular Magnetic Resonance. 2019; 21; 6. doi: 10.1186/s12968-018-0513-4.
78. Plana J., Thavendiranathan P., Bucciarelli-Ducci C., Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC: Cardiovascular Imaging. 2018; 11 (8): 1173–1186. doi: 10.1016/j.jcmg.2018.06.003.
79. Becker M. M. C., Arruda G. F. A., Berenguer D. R. F., Buril R. O., Cardinale D., Brandão S. C. S. Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. Cardio-Oncology. 2023; 9 (1); 17. doi: 10.1186/s40959-023-00161-6.
80. Kim J., Feller E. D., Chen W., Liang Y., Dilsizian V. FDG PET/CT for early detection and localization of left ventricular assist device infection: impact on patient management and outcome. JACC: Cardiovascular Imaging. 2019; 12 (4): 722–729. doi: 10.1016/j.jcmg.2018.01.024.
81. Simoni L. J. C., Brandão S. C. S. New imaging methods for detection of drug-induced cardiotoxicity in cancer patients. Current Cardiovascular Imaging Reports. 2017; 10 (6); 1–11. doi: 10.1007/s12410-017-9415-3.
82. Mahabadi A. A., Rischpler C. Cardiovascular imaging in cardio-oncology. Journal of Thoracic Disease. 2018; 10, suppl. 35: S4351–S4366. doi: 10.21037/jtd.2018.10.92.
83. Wetscherek M. T. A., McNaughton E., Majcher V., Wetscherek A., Sadler T. J., Alsinbili A., Teh W. H., Moore S. D., Patel N., Smith W. P. W., Krishnan U. Incidental coronary artery calcification on non-gated CT thorax correlates with risk of cardiovascular events and death. European Radiology. 2023; 33 (7): 4723–4733. doi: 10.1007/s00330-023-09428-z.
84. Lehmann N., Erbel R., Mahabadi A. A., Rauwolf M., Möhlenkamp S., Moebus S., Kälsch H., Budde T., Schmermund A., Stang A., Führer-Sakel D., Weimar C., Roggenbuck U., Dragano N., Jöckel K. H.; Heinz Nixdorf Recall Study Investigators. Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf Recall). Circulation. 2018; 137 (7): 665–679. doi: 10.1161/CIRCULATIONAHA.116.027034.
85. Patel S., Franco F. X., McDonald M., Rivera C., Perez-Villa B., Collier P., Moudgil R., Gupta N., Sadler D. B. Use of computed tomography coronary calcium score for prediction of cardiovascular events in cancer patients: a retrospective cohort analysis. Cardio-Oncology. 2024; 10 (1); 1. doi: 10.1186/s40959-023-00196-9.
86. Borowiec A., Ozdowska P., Rosinska M., Zebrowska A. M., Jagiello-Gruszfeld A., Jasek S., Waniewska J., Kotowicz B., Kosela-Paterczyk H., Lampka E., Pogoda K., Cieszanowski A., Nowecki Z., Walewski J. Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity. Cardio-Oncology. 2024; 10 (1); 64. doi: 10.1186/s40959-024-00266-6.
Review
For citations:
Podsevalov V.S., Sabanova V.D., Germanova O.A., Davydkin I.L. Current understanding of cardiotoxicity diagnostics in patients with multiple myeloma during autologous hematopoietic stem cell transplantation. Astrakhan medical journal. 2025;20(2):8-26. (In Russ.) https://doi.org/10.17021/1992-6499-2025-2-08-26
Views:
42
Email this article 